What Is the Somogyi Effect? Morning Highs, Dawn Phenomenon, and How to Tell Them Apart

What Is the Somogyi Effect?

The Somogyi effect is a rebound surge in blood glucose triggered by the body's own defense against low blood sugar during sleep. When glucose falls below roughly 70 mg/dL overnight, the pancreas releases glucagon, the adrenal glands release epinephrine and cortisol, and growth hormone rises. These counter-regulatory signals instruct the liver to dump stored glycogen into the bloodstream, and glucose climbs well above normal before the person wakes.

Michael Somogyi, a Hungarian-American biochemist at Washington University in St. Louis, first described this rebound pattern in the 1930s. He proposed it as the explanation for why some patients on insulin ran paradoxically high fasting readings despite seemingly adequate or even excessive overnight dosing. The practical implication was striking: reducing the evening insulin dose could, counterintuitively, lower morning glucose. That logic is still applied clinically today, even though the magnitude and prevalence of the effect have been debated in the literature for decades.

A 1988 study by Gale and colleagues published in the British Medical Journal found that nocturnal hypoglycemia preceded morning hyperglycemia in a meaningful subset of insulin-treated patients, supporting Somogyi's core mechanism [1]. Later CGM-era research has refined that picture significantly, showing the phenomenon is real but less common than once assumed, occurring in roughly 25-30% of patients who present with unexplained morning highs [2].

The physiological sequence matters for treatment. If a clinician increases the evening insulin dose assuming the morning high is simply under-treatment, the nocturnal low deepens and the rebound worsens. Checking blood glucose at 2 a.m. to 3 a.m., either with a fingerstick or a CGM trace, is the standard diagnostic step recommended by the American Diabetes Association (ADA) 2024 Standards of Care [3].

How the Somogyi Effect Differs from Dawn Phenomenon

Both the Somogyi effect and dawn phenomenon produce high fasting glucose, but the upstream cause is completely different. Dawn phenomenon does not involve a preceding hypoglycemic episode.

Between roughly 2 a.m. and 8 a.m., the body releases a pulse of growth hormone as part of normal circadian physiology. Growth hormone antagonizes insulin action and signals the liver to increase glucose output. Cortisol follows a similar morning rise. In people without diabetes, a small compensatory insulin release keeps glucose stable. In people with type 1 or type 2 diabetes, that compensatory response is absent or insufficient, so fasting glucose rises into the 140-180 mg/dL range without any overnight low [4].

The distinction matters completely for treatment. Dawn phenomenon calls for increased basal insulin coverage or repositioning the timing of a long-acting dose. The Somogyi effect calls for reducing the evening dose, adding a bedtime snack, or switching to a different insulin formulation. Treating dawn phenomenon with a Somogyi protocol, or vice versa, worsens control.

The CGM has made this diagnostic question largely answerable without guesswork. A flat or gently rising overnight glucose trace that ascends sharply after 4 a.m. points to dawn phenomenon. A trace that dips below 70 mg/dL around 2 a.m. to 3 a.m. and then climbs rapidly points to Somogyi rebound [5]. The ADA's 2024 guidelines state directly that continuous glucose monitoring "provides clinically actionable data on nocturnal hypoglycemia that fingerstick testing alone cannot reliably detect" [3].

A useful three-question clinical framework for sorting morning highs:

1. Does the CGM or 3 a.m. fingerstick show glucose below 70 mg/dL? If yes, suspect Somogyi. Reduce the evening basal or premixed insulin dose by 10-20% and recheck over 3-5 nights.
2. Does glucose rise steadily from 4 a.m. onward without a preceding low? If yes, suspect dawn phenomenon. Consider moving the long-acting dose to bedtime or adding an early-morning rapid-acting correction.
3. Is the morning high explained by a late carbohydrate-heavy meal or a missed evening dose? Rule out dietary and adherence causes first before attributing the pattern to either physiological mechanism.

What Is a Normal A1c and Why Does It Matter Here?

A1c (glycated hemoglobin) reflects average blood glucose over the preceding 8-12 weeks and gives a broader picture that any single fasting measurement cannot capture. Recurring Somogyi episodes can falsely reassure: the overnight low and the morning high may average out to an A1c that looks acceptable, while the patient is actually cycling through dangerous glucose swings multiple times per week [6].

Normal A1c for an adult without diabetes sits below 5.7%. The ADA classifies 5.7%-6.4% as prediabetes and 6.5% or higher on two separate tests as diabetes [3]. For most adults already diagnosed with diabetes, the ADA recommends an A1c target below 7.0%, a threshold associated with substantially reduced risk of microvascular complications in the landmark DCCT trial (N=1,441), which showed that intensive control reducing A1c from approximately 9.0% to 7.2% cut the risk of diabetic retinopathy progression by 76% [7].

A1c does have limits. It reflects an average, not variability. Two patients can share an identical A1c of 7.0% while one runs a smooth daily glucose curve and the other swings from 40 mg/dL to 280 mg/dL every night. Time in range (TIR), defined as the percentage of readings between 70 and 180 mg/dL, is now recognized alongside A1c as a meaningful outcome metric. The ADA and the Advanced Technologies and Treatments for Diabetes (ATTD) consensus group recommend a TIR target above 70% for most adults with type 1 or type 2 diabetes [8].

For patients experiencing suspected Somogyi effect, an A1c in a seemingly acceptable range does not rule out the problem. CGM-derived glucose variability metrics, particularly coefficient of variation (CV) and time below range (TBR), are the tools that expose the pattern [5].

What Blood Sugar Levels Are Dangerous?

Glucose levels at both extremes carry acute risk. The ADA uses a three-level classification for hypoglycemia [3]:

• Level 1: glucose below 70 mg/dL. The person is alert and can self-treat with 15-20 grams of fast-acting carbohydrate. This is the threshold where counter-regulatory hormones begin to activate, making it the starting point of a potential Somogyi sequence.
• Level 2: glucose below 54 mg/dL. Clinically significant hypoglycemia requiring immediate intervention. Cognitive impairment, seizure, and loss of consciousness become likely at this level.
• Level 3: severe hypoglycemia, defined by altered consciousness requiring external assistance, regardless of the glucose number.

Nocturnal hypoglycemia reaching Level 2 is particularly dangerous because the sleeping person cannot recognize symptoms or self-treat. A 2023 analysis in Diabetes Care (N=4,539 CGM users) found that 36% of hypoglycemic events in insulin-treated patients occurred between midnight and 6 a.m., and 62% of those episodes went unrecognized [9].

On the hyperglycemia side, sustained glucose above 300 mg/dL warrants urgent clinical evaluation. Above 600 mg/dL, the risk of hyperosmolar hyperglycemic state (HHS) becomes significant; HHS carries a reported mortality of 5-20% in hospitalized patients [10]. Diabetic ketoacidosis (DKA) can develop at lower glucose levels, particularly in type 1 diabetes, and is marked by blood glucose typically above 250 mg/dL combined with ketones and acidosis [11].

Normal fasting glucose sits between 70 and 99 mg/dL. Postprandial glucose (two hours after eating) below 140 mg/dL is the threshold the ADA uses to define normal glucose tolerance [3]. The DECODE study (N=22,514) demonstrated that two-hour postprandial glucose predicted cardiovascular mortality independently of fasting glucose, underscoring the clinical relevance of post-meal readings beyond the fasting number alone [12].

Why Do People with Diabetes Get Morning Highs?

Morning hyperglycemia in diabetes traces to at least four distinct mechanisms, and they can overlap.

Somogyi rebound. As described above, nocturnal hypoglycemia stimulates counter-regulatory hormones that overshoot glucose correction. The fix is reducing overnight insulin exposure [1].

Dawn phenomenon. The physiological circadian cortisol and growth hormone surge between 2 a.m. and 8 a.m. raises hepatic glucose output without a preceding low. Prevalence in type 2 diabetes is estimated at 54% in a study published in Diabetes Care (N=248) by Monnier and colleagues [13]. The fix is adjusting basal insulin dose or timing.

Waning insulin. A long-acting insulin dose administered too early in the evening may lose its effectiveness by 3 a.m. to 4 a.m. This produces a rising glucose trace without the sharp rebound characteristic of Somogyi and without the circadian hormone signature of dawn phenomenon. Switching to a longer-duration basal insulin such as insulin degludec (Tresiba), which has a half-life exceeding 25 hours, often resolves this [14].

Evening carbohydrate load. A meal heavy in refined carbohydrates or fat-delayed digestion (gastroparesis pattern) can continue raising glucose past midnight and into the early morning hours. This is the most straightforward cause and is ruled out first by dietary review.

Distinguishing among these requires either a CGM trace covering the full overnight period or a structured fingerstick protocol at bedtime, 2 a.m. to 3 a.m., and fasting. No single symptom pattern reliably separates them at the bedside without glucose data [3].

How Insulin Affects Blood Sugar: The Core Physiology

Insulin is secreted by pancreatic beta cells in response to rising blood glucose, particularly after meals. It binds to receptors on muscle, fat, and liver cells, triggering glucose uptake and suppressing hepatic glucose production. In type 1 diabetes, beta cells are destroyed and endogenous insulin is absent. In type 2 diabetes, peripheral insulin resistance forces beta cells to produce more insulin until they can no longer keep pace with demand [15].

Exogenous insulin comes in several formulations with distinct pharmacokinetic profiles that directly determine overnight glucose behavior. Rapid-acting analogs such as lispro (Humalog) peak in 30-90 minutes and clear in 3-5 hours. Long-acting analogs such as glargine (Lantus) have a relatively flat profile over 20-24 hours but can still cause nocturnal hypoglycemia if dosed too aggressively relative to carbohydrate intake and activity level [16].

The ORIGIN trial (N=12,537) tested whether early basal insulin glargine in people with prediabetes or early type 2 diabetes would reduce cardiovascular events. It did not reduce events, but it did normalize fasting glucose and reduced the rate of incident diabetes by 28% over a median of 6.2 years, demonstrating the metabolic significance of precisely managed basal insulin coverage [17].

Nocturnal hypoglycemia risk increases with any of the following: skipping the evening meal, unplanned physical activity late in the day, alcohol consumption (which suppresses hepatic glycogenolysis), or a mismatch between the peak of an evening insulin dose and overnight carbohydrate availability [3].

Diagnosing the Somogyi Effect: A Step-by-Step Clinical Approach

Diagnosis requires overnight glucose data. No symptom alone is diagnostic.

Step 1: CGM review. A minimum 7-day CGM trace showing overnight glucose patterns is the most efficient starting point. Look for any dip below 70 mg/dL between 10 p.m. and 4 a.m. followed by glucose above 140 mg/dL by 6 a.m. to 8 a.m.

Step 2: Structured fingerstick protocol if CGM is unavailable. Check glucose at bedtime, at 2 a.m. to 3 a.m., and again fasting. If the 3 a.m. reading is below 70 mg/dL and the fasting reading is above 140 mg/dL, the Somogyi pattern is likely [3].

Step 3: Rule out dietary and medication timing causes. Review the prior evening's meal composition, alcohol intake, and the type and timing of all insulin doses.

Step 4: Therapeutic trial. Reduce the evening basal or premixed insulin dose by 10-20%. Monitor for 5-7 nights. If morning glucose improves and the 3 a.m. low resolves, the Somogyi diagnosis is confirmed by response.

Step 5: Consider insulin formulation change. If waning insulin is contributing, switching from NPH or glargine U-100 to insulin degludec or glargine U-300 may reduce the overnight nadir without sacrificing fasting control [14].

An endocrinology consultation is appropriate when the cause remains unclear after two structured trials, when Level 2 hypoglycemia is occurring regularly, or when A1c does not reflect the glucose variability visible on CGM.

Treatment and Prevention of the Somogyi Effect

Treatment targets the nocturnal low, not the morning high. Chasing the morning high with more evening insulin worsens the underlying problem.

Reduce evening insulin dose. A 10-20% reduction in the dose driving the overnight low is the first step. This applies to NPH, premixed 70/30 formulations, and any intermediate-acting insulin given with dinner [3].

Redistribute carbohydrate. A small bedtime snack containing 15-20 grams of slow-digesting carbohydrate (for example, whole-grain crackers with peanut butter) can blunt a nocturnal glucose nadir in patients on fixed insulin regimens. This is particularly useful for patients on NPH, which peaks 4-8 hours after injection [16].

Switch to a flatter basal insulin. Insulin degludec (Tresiba) and glargine U-300 (Toujeo) both reduce the risk of nocturnal hypoglycemia compared with glargine U-100. A 2017 meta-analysis in Diabetes, Obesity and Metabolism (N=18,684 across 24 trials) found that degludec reduced confirmed nocturnal hypoglycemia by 36% compared with glargine U-100 in type 1 diabetes (relative risk 0.64 to 95% CI 0.56-0.73, P<0.001) [18].

Closed-loop insulin delivery. Hybrid closed-loop systems (also called artificial pancreas systems) use CGM-directed automated insulin delivery to reduce both nocturnal hypoglycemia and morning rebound. The CLOSED trial and subsequent real-world data have shown that time below range decreases to below 1% in most users within 3 months of initiation [19].

Alcohol counseling. Patients should understand that alcohol suppresses hepatic gluconeogenesis for up to 12 hours after consumption, substantially increasing the risk of overnight hypoglycemia in insulin-treated individuals. The ADA recommends that people with diabetes who choose to drink do so with food and monitor glucose more frequently [3].

GLP-1 Receptor Agonists and Their Role in Overnight Glucose Stability

GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and dulaglutide (Trulicity) do not directly cause hypoglycemia when used as monotherapy because their insulin-stimulating effect is glucose-dependent. When added to basal insulin regimens, however, they frequently allow a 20-30% reduction in the required insulin dose, which in turn reduces nocturnal hypoglycemia risk [20].

The SUSTAIN-5 trial (N=397) found that adding once-weekly semaglutide 1.0 mg to basal insulin allowed a mean insulin dose reduction of 20% while achieving an A1c reduction of 1.4 percentage points versus 0.1 for placebo over 30 weeks [20]. Patients on combined GLP-1 plus basal insulin regimens should have their evening insulin dose proactively reviewed when the GLP-1 agent is initiated to avoid creating a Somogyi-triggering nocturnal low.

The STEP-1 trial (N=1,961) tested semaglutide 2.4 mg subcutaneously once weekly for weight loss in adults without diabetes and found a mean weight reduction of 14.9% at 68 weeks versus 2.4% for placebo (P<0.001) [21]. Weight loss at that magnitude substantially improves insulin sensitivity, which in people with type 2 diabetes on insulin often necessitates basal dose reduction to prevent nocturnal lows.